NCT01270945View on ClinicalTrials.gov

Safety and Preliminary Efficacy Study of an Anti-inflammatory Therapeutic Antibody in Reducing Restenosis.

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

June 30, 2011

Primary Completion Date

September 30, 2013

Study Completion Date

April 30, 2014

Conditions

Patients Undergoing Repeat Peripheral Artery Revascularization

Interventions

DRUG

CV-18C3

3.75mg/kg given IV for a period of 6 weeks, followed by subcutaneous administration

PROCEDURE

Standard of Care

Trial Locations (8)

31799

John D. Archbold Memorial Hospital, Thomasville

32207

River City Clinical Research, Jacksonville

32216

Jacksonville Center for Clinical Research, Jacksonville

33462

JFK Medical Center, Atlantis

34471

Mediquest Research Group, Ocala

45267

Univeristy of Cincinnati University Hospital, Cincinnati

77030

Methodist Hospital, Houston

95819

Sutter Heart & Vascular Institute, Sacramento

All Listed Sponsors

lead

Janssen Research & Development, LLC

INDUSTRY

NCT01270945 - Safety and Preliminary Efficacy Study of an Anti-inflammatory Therapeutic Antibody in Reducing Restenosis. | Biotech Hunter | Biotech Hunter